dc.creator | Carrasco Hernández, Laura | es |
dc.creator | Caballero Eraso, Candela | es |
dc.creator | Ruiz Duque, Borja | es |
dc.creator | Abad Arranz, María | es |
dc.creator | Márquez Martín, Eduardo | es |
dc.creator | Calero Acuña, Carmen | es |
dc.creator | López-Campos Bodineau, José Luis | es |
dc.date.accessioned | 2021-09-09T12:10:56Z | |
dc.date.available | 2021-09-09T12:10:56Z | |
dc.date.issued | 2021-04-15 | |
dc.identifier.citation | Carrasco Hernández, L., Caballero Eraso, C., Ruiz Duque, B., Abad Arranz, M., Márquez Martín, E., Calero Acuña, C. y López-Campos Bodineau, J.L. (2021). Predictors of single bronchodilation treatment response for copd: an observational study with the trace database cohort. Journal of Clinical Medicine, 10 (8) | |
dc.identifier.issn | 2077-0383 | es |
dc.identifier.uri | https://hdl.handle.net/11441/125606 | |
dc.description.abstract | Chronic obstructive pulmonary disease (COPD) patients constitute a heterogeneous population in terms of treatment response. Our objective was to identify possible predictive factors of response to treatment with single bronchodilation monotherapy in patients diagnosed with COPD. The Time-based Register and Analysis of COPD Endpoints (TRACE; clinicaltrials.gov NCT03485690) is a prospective cohort of COPD patients who have been attending annual visits since 2012. Patients who were kept on a single bronchodilator during the first year of follow-up were selected. The responders were defined according to all of the following variables: any improvement in morning post-dose forced expiratory volume in 1 s or deterioration <100 mL, no change or improvement in dyspnea score, and no occurrence of exacerbations. Significant and plausible variables were analyzed using a proportional hazard Cox regression for single bronchodilator responders. We analyzed 764 cases, of whom 128 (16.8%) were receiving monotherapy with one bronchodilator. Of these, 85 patients (66.4%) were responders. Factors affecting responder status were: female gender (hazard ratio (HR) 0.276; 95% confidence interval (CI) 0.089–0.858), dyslipidemia (HR 0.436; 95%CI 0.202–0.939), not performing regular exercise (HR 0.523; 95%CI 0.254–1.076), active smoking (HR 0.413; 95%CI 0.186–0.920), and treatment adherence (HR 2.527; 95%CI 1.271–5.027). The factors associated with a single bronchodilation response are mainly non-pharmacological interventions and comorbidities. | es |
dc.description.sponsorship | Gebro Pharma | es |
dc.format | application/pdf | es |
dc.format.extent | 8 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Journal of Clinical Medicine, 10 (8) | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | COPD | es |
dc.subject | Long-acting bronchodilators | es |
dc.subject | Clinical response | es |
dc.subject | Pharmacological | es |
dc.title | Predictors of single bronchodilation treatment response for copd: an observational study with the trace database cohort | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.mdpi.com/2077-0383/10/8/1708 | es |
dc.identifier.doi | 10.3390/jcm10081708 | es |
dc.journaltitle | Journal of Clinical Medicine | es |
dc.publication.volumen | 10 | es |
dc.publication.issue | 8 | es |